FDA Expands Use of Approved Breast Cancer Drug : RushPRNews - Newswire & Global Press Release Distribution

 
Bookmark and Share

FDA Expands Use of Approved Breast Cancer Drug

February 1, 2010

Washington D.C. (rushPRnews) 02/01/10 — Provides oral regime for hormone positive and HER2-positive advanced breast cancer

The U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated.

HER2 is a protein involved in normal cell growth. It is found on some types of cancer cells, including breast cancer cells. In hormone positive breast cancer, the presence of certain hormones contributes to breast cancer growth. In HER2-positive breast cancer, stimulation of the HER2 receptor contributes to cancer cell growth. Breast cancer is the second leading cause of death among women. More than 192,000 women will be diagnosed with breast cancer this year.

“This drug combination of Tykerb plus Femara provides women being treated for advanced breast cancer with an important treatment option. This entirely oral treatment regimen works by targeting both HER2 and the hormone receptors, thereby slowing the cancer cells’ ability to grow or spread,” said Richard Pazdur, M.D., director of the Office of Oncology Drug Products, in the FDA’s Center for Drug Evaluation and Research.

Women with HER2-positive disease receiving the Tykerb plus Femara combination more than doubled the time they lived without the cancer progressing compared with those receiving Femara alone (35 weeks vs. 13 weeks). Women in the company sponsored study were randomized to receive Tykerb plus Femara or Femara alone. It is too early to determine whether an improvement in overall survival will be observed in the clinical trial.

Tykerb works by depriving tumor cells of signals needed to grow. Tykerb enters the cell and blocks the function of the HER2 protein.

Tykerb was initially approved in combination with a chemotherapy drug, Xeloda (capecitabine) in 2007. This combination was used to treat women with advanced breast cancer tumors with the HER2 protein who had received prior treatment with chemotherapy drugs, including an anthracycline and a taxane, and Herceptin (trastuzumab), an anti-cancer antibody used to treat HER2-positive advanced breast cancer.

Safety information from this study was consistent with previous Tykerb clinical studies in advanced breast cancer. The most commonly reported side effects of the combination were diarrhea, rash, nausea and fatigue. Treatment with Tykerb also has been associated with decreases in heart function, liver damage, and lung tissue inflammation. Fetal harm may occur if used to treat advanced breast cancer in pregnant women. Patients should talk to their health care provider about the potential side effects, drug interactions, and other medical conditions.

 

Tykerb is marketed by Collegeville, Pa.-based GlaxoSmithKline.
Femara is marketed by Lebanon, Pa.-based Novartis AG.

 

For more information:

 

FDA Office of Oncology Drug Products
http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm091745.htm

 

National Cancer Institute – Breast Cancer
http://www.cancer.gov/cancertopics/types/breast

 

RSS Feed for FDA News Releases [what is RSS?]

About the author:

FDA is an agency within the Department of Health and Human Services and consists of seven centers and offices

Click here to see all news from this author/company

Filed Under: FDA- Pharmaceutical news, Health and Fitness, Food-Nutrition, Lifestyle, PRESS RELEASE

RUSH PR NEWS newswire and press release services at rushprnews.com / AH Marketing ahmarketinggroup.com

Content- Legal Responsibility - All material is copyrighted - You may repost but you MUST link back to the original post on your page and acknowledge Rush PR News as the news source. Rush PR News is not legally and/or morally responsible for content of press releases, opinions expressed or fact-checking.

Rush PR News cannot be held legally responsible for material published and distributed through its newswire service or published in its press-room and therefore cannot be sued for published material. Third-party must be contacted directly to dispute content.

Rush PR News is not the contact for material published.

RSSFeed PRESS & SOCIAL MEDIA RELEASES

Newborn Foundation Selected Among First 
Global Innovation Fund Grant Recipients

Saint Paul, MN 02/09/16 · Announcement at GIF launch event in London highlights...

The Gamifiers Partners With Livecube to Bring Gamified Event Engagement to the Middle East

DUBAI/NEW YORK 02/02/16 · TECH NEWS - The Gamifiers, the leading specialized gamification...

Rugby North to Launch Canada’s First Professional Rugby League

Toronto, ON 02/02/16 ·  The country that introduced rugby to North America...

Dominion Lending Centres Edge Financial Welcomes New Mortgage Agents On Board

Toronto, Ontario 01/27/16 · The mortgage agents behind the site GTAMortgagePros.com  –...

Black Films Matter supports Movie Binges on Oscar Night

HOLLYWOOD, CA 01/26/16 · The Advocacy group Black Films Matter is supporting...

The Big Freeze: America Due Extreme Snowstorms

NEW YORK 01/23/16 · Founder of GridLocate.com, offers advice to US residents...

Clean the world Canada choisit Moisson Montréal

MontrĂ©al, QuĂ©bec 01/05/16 · Clean the World Canada choisit Moisson Montréal comme...

All I Want for Christmas is for Trump to Shut Up is Island's new National Anthem

Cambridge, Mass 12/22/15 ·  A satirical Christmas song poking fun at real...

Gotham City Networking, Inc. Honors Raj Goel with Networker of the Year Award

New York, NY 12/16/15 · On Wednesday, December 2nd, Gotham City Networking, Inc....

Brainlink International Received Renowned Award for a Corporate SOP Culture That Outshines the Rest

New York, NY 12/15/15 · On Thursday, December 3rd, 2015, SmartCEO awarded Brainlink...

Livecube Enhances Its Social Engagement App to Be a Single Dashboard for Event Organizers

NEW YORK 12/03/15 · Enhanced features include real-time direct chat between attendees,...

MLBC offers new IFRS consulting service

Toronto, Ontario 12/01/15 · MLBC offers new IFRS consulting service New IFRS accounting...

For a fistful of dollars two gangs continue to fleece innocent families

Dallas, Texas 12/01/15 · Jaime Escalona speaking on behalf of COViSAL denounces...